Last reviewed · How we verify
Simvastatin (Zocor)
Simvastatin (Zocor) is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by New York State Psychiatric Institute. It is currently FDA-approved for Hypercholesterolemia and mixed dyslipidemia, Primary prevention of coronary heart disease, Secondary prevention of cardiovascular events in patients with established coronary heart disease. Also known as: Zocor.
Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and mixed dyslipidemia, Primary prevention of coronary heart disease, Secondary prevention of cardiovascular events in patients with established coronary heart disease.
At a glance
| Generic name | Simvastatin (Zocor) |
|---|---|
| Also known as | Zocor |
| Sponsor | New York State Psychiatric Institute |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Simvastatin is a statin that competitively inhibits HMG-CoA reductase, blocking the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This leads to decreased hepatic cholesterol production, upregulation of LDL receptors on liver cells, and enhanced clearance of LDL cholesterol from the bloodstream. The net result is significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.
Approved indications
- Hypercholesterolemia and mixed dyslipidemia
- Primary prevention of coronary heart disease
- Secondary prevention of cardiovascular events in patients with established coronary heart disease
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes (ALT/AST)
- Headache
- Rhabdomyolysis (rare)
- Nausea
Key clinical trials
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis (PHASE2)
- Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer (PHASE1, PHASE2)
- Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer (PHASE2)
- Clinical Evaluation of Simcyp-Guided Simvastatin Dosing in Patients With Liver Cirrhosis (PHASE4)
- Triple Antibiotic Paste vs Simvastatin for Lesion Sterilization and Tissue Repair in Primary Molars. (PHASE2)
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Simvastatin (Zocor) CI brief — competitive landscape report
- Simvastatin (Zocor) updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI
Frequently asked questions about Simvastatin (Zocor)
What is Simvastatin (Zocor)?
How does Simvastatin (Zocor) work?
What is Simvastatin (Zocor) used for?
Who makes Simvastatin (Zocor)?
Is Simvastatin (Zocor) also known as anything else?
What drug class is Simvastatin (Zocor) in?
What development phase is Simvastatin (Zocor) in?
What are the side effects of Simvastatin (Zocor)?
What does Simvastatin (Zocor) target?
Related
- Drug class: All HMG-CoA reductase inhibitor (statin) drugs
- Target: All drugs targeting HMG-CoA reductase
- Manufacturer: New York State Psychiatric Institute — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypercholesterolemia and mixed dyslipidemia
- Indication: Drugs for Primary prevention of coronary heart disease
- Indication: Drugs for Secondary prevention of cardiovascular events in patients with established coronary heart disease
- Also known as: Zocor
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing